T-lymphocyte alloresponses of campath-1H-treated kidney transplant patients

Transplantation

Volumn 81, Issue 1, 2006, Pages 81-87

  Bloom, Debra D ^a,b   Hu, Huaizhong ^a   Fechner, John H ^a   Knechtle, Stuart J ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b Department of Surgery ^*  (United States)

Author keywords

Alloresponse; Campath 1H; T lymphocyte

Indexed keywords

ALEMTUZUMAB; ALLOANTIGEN; BASILIXIMAB; CARBOXYFLUORESCEIN DIACETATE SUCCINIMIDYL ESTER; CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CYCLOSPORIN A; GAMMA INTERFERON; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; STEROID; TACROLIMUS;

ADULT; ALLOIMMUNITY; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT; MONOTHERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENAL GRAFT DYSFUNCTION; T LYMPHOCYTE;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; CELL PROLIFERATION; CYTOKINES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ISOANTIGENS; KIDNEY TRANSPLANTATION; KINETICS; LYMPHOCYTE COUNT; LYMPHOCYTE DEPLETION; MIDDLE AGED; T-LYMPHOCYTES; TIME FACTORS; TREATMENT OUTCOME;

EID: 31044451821     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000191940.13473.59     Document Type: Article

References (21)

1. Buggins AG, Mufti GJ, Salisbury J, et al. Peripheral Blood but Not Tissue Dendritic Cells Express CD52 and Are Depleted by Treatment With Alemtuzumab. Blood 2002; 100 (5): 1715.
2. Ratzinger G, Reagan JL, Heller G, et al. Differential CD52 Expression by Distinct Myeloid Dendritic Cell Subsets: Implications for Alemtuzumab Activity at the Level of Antigen Presentation in Allogeneic Graft-Host Interactions in Transplantation. Blood 2003; 101 (4): 1422.
3. Riechmann L, Clark M, Waldmann H, Winter G. Reshaping Human-Antibodies for Therapy. Nature 1988; 332 (6162): 323.
4. Moreau T, Coles A, Wing M, et al. CAMPATH-IH in Multiple Sclerosis. Mult Scler 1996; 1 (6): 357.
5. Confavreux C, Vukusi S. Non-Specific Immunosuppressants in the Treatment of Multiple Sclerosis. Clin Neurol Neurosurg 2004; 106 (3): 263.
6. Cohen Y, Nagle A. Treatment of Refractory Autoimmune Diseases With Ablative Immunotherapy. Autoimmun Rev 2004; 3 (2): 21.
7. Hale G, Slavin S, Goldman JM, et al. Alemtuzumab (Campath-1H) for Treatment of Lymphoid Malignancies in the Age of Nomnyeloablative Conditioning? Bone Marrow Transplantation 2002; 30 (12): 797.
8. Calne R, Moffatt SD, Friend PJ, et al. Prope Tolerance With Induction Using Campath 1H and Low-Dose Cyclosporin Monotherapy in 31 Cadaveric Renal Allograft Recipients. Nippon Geka Gakkai Zasshi 2000; 101 (3): 301.
9. Knechtle SJ, Pirsch JD, Fechner H, et al. Campath-1H Induction Plus Rapamycin Monotherapy for Renal Transplantation: Results of a Pilot Study. Am J Transplant 2003; 3 (6): 722.
10. Garcia M, Weppler D, Mittal N, et al. Campath-1H Immunosuppressive Therapy Reduces Incidence and Intensity of Acute Rejection in Intestinal and Multivisceral Transplantation. Transplant Proc 2004; 36 (2): 323.
11. Kandaswamy R, Gruessner R, Gruessner A, et al. Calcineruin Inhibitor (CI) and Steroid-Free Immunosuppression (ImmSx) for Pancreas (Px) and Px-Kidney (KD) Recipients Using Campath for Both Induction and Maintenance (Maint.). Am J Transplant 2004; 4: 536.
12. Kirk AD, Hale DA, Mannon RB, et al. Results From a Human Renal Allograft Tolerance Trial Evaluating the Humanized CD52-Specific Monoclonal Antibody Alemtuzumab (CAMPATH-1H). Transplantation 2003; 76 (1): 120.
13. Knechtle SJ, Fernandez LA, Pirsch JD, et al. Campath-1H in Renal Transplantation: The University of Wisconsin Experience. Surgery 2004;136(4):754.
14. Brett S, Baxter G, Cooper H, et al. Repopulation of Blood Lymphocyte Sub-Populations in Rheumatoid Arthritis Patients Treated With the Depleting Humanized Monoclonal Antibody, CAMPATH-1H. Immunology 1996; 88(1): 13.
15. Zheng Y, Manzotti CN, Liu M, et al. CD86 and CD80 Differentially Modulate the Suppressive Function of Human Regulatory T Cells. J Immunol 2004; 172 (5): 2778.
16. Sansom DM, Manzotti CN, Zhen Y. What's the Difference Between CD80 and CD86? Trends Immunol 2003; 24 (6): 314.
17. Game DS, Hernandez-Fuentes MP, Chaudhry AN, Lechle RI. CD4+CD25+ Regulatory T Cells Do Not Significantly Contribute to Direct Pathway Hyporesponsiveness in Stable Renal Transplant Patients. J Am Soc Nephrol 2003; 14 (6): 1652.
18. Gavin MA, Clarke SR, Negrou E, et al. Homeostasis and Anergy of CD4(+)CD25(+) Suppressor T Cells in Vivo. Nat Immunol 2002; 3 (1): 33.
19. Baan CC, van der Mas BJ, Klepper M, et al. Differential Effect of Calcineurin Inhibitors, Anti-CD25 Antibodies and Rapamycin in Human on the Induction of FOXP3 T Cells. Transplantation 2005; 80 (1): 110.
20. Liu Z, Tugulea S, Cortesini R, Suciu-Foc N. Specific Suppression of T Helper Alloreactivity by Allo-MHC Class I-Restricted CD8(+) CD28(-) T Cells. Int Immunol 1998; 10 (6): 775.
21. Zhang PL, Malek SK, Prichard JW, et al. Monocytes Are Dominant Inflammatory Cells for Acute Renal Rejection After Combined Treatment With Preoperative Campath-1H and Postoperative Immunosuppression. Am J Transplant 2004; 4: 404.